148 related articles for article (PubMed ID: 21084860)
1. Aggressive myeloid leukemia formation is directed by the Musashi 2/Numb pathway.
Griner LN; Reuther GW
Cancer Biol Ther; 2010 Nov; 10(10):979-82. PubMed ID: 21084860
[TBL] [Abstract][Full Text] [Related]
2. Regulation of myeloid leukaemia by the cell-fate determinant Musashi.
Ito T; Kwon HY; Zimdahl B; Congdon KL; Blum J; Lento WE; Zhao C; Lagoo A; Gerrard G; Foroni L; Goldman J; Goh H; Kim SH; Kim DW; Chuah C; Oehler VG; Radich JP; Jordan CT; Reya T
Nature; 2010 Aug; 466(7307):765-8. PubMed ID: 20639863
[TBL] [Abstract][Full Text] [Related]
3. Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia.
Kaeda J; Ringel F; Oberender C; Mills K; Quintarelli C; Pane F; Koschmieder S; Slany R; Schwarzer R; Saglio G; Hemmati P; van Lessen A; Amini L; Gresse M; Vagge E; Burmeister T; Serra A; Carson A; Schwarz M; Westermann J; Jundt F; Dörken B; le Coutre P
Leuk Lymphoma; 2015 Jul; 56(7):2105-13. PubMed ID: 25363400
[TBL] [Abstract][Full Text] [Related]
4. NUMB inactivation confers resistance to imatinib in chronic myeloid leukemia cells.
García-Alegría E; Lafita-Navarro MC; Aguado R; García-Gutiérrez L; Sarnataro K; Ruiz-Herguido C; Martín F; Bigas A; Canelles M; León J
Cancer Lett; 2016 May; 375(1):92-99. PubMed ID: 26944313
[TBL] [Abstract][Full Text] [Related]
5. Blast crisis Ph+ chronic myeloid leukemia with NUP98/HOXA13 up-regulating MSI2.
Di Giacomo D; Pierini V; Barba G; Ceccarelli V; Vecchini A; Mecucci C
Mol Cytogenet; 2014; 7():42. PubMed ID: 24971156
[TBL] [Abstract][Full Text] [Related]
6. Cooperation of Musashi-2, Numb, MDM2, and P53 in drug resistance and malignant biology of pancreatic cancer.
Sheng W; Dong M; Chen C; Wang Z; Li Y; Wang K; Li Y; Zhou J
FASEB J; 2017 Jun; 31(6):2429-2438. PubMed ID: 28223335
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of expression levels of stem cell regulators MSI2 and NUMB in acute myeloid leukemia.
Thol F; Winschel C; Sonntag AK; Damm F; Wagner K; Chaturvedi A; Göhring G; Schlegelberger B; Lübbert M; Fiedler W; Kirchner H; Krauter J; Ganser A; Heuser M
Ann Hematol; 2013 Mar; 92(3):315-23. PubMed ID: 23233047
[TBL] [Abstract][Full Text] [Related]
8. Distinct expression profiles of MSI2 and NUMB genes in myelodysplastic syndromes and acute myeloid leukemia patients.
Pereira JK; Traina F; Machado-Neto JA; Duarte Ada S; Lopes MR; Saad ST; Favaro P
Leuk Res; 2012 Oct; 36(10):1300-3. PubMed ID: 22784712
[TBL] [Abstract][Full Text] [Related]
9. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
[TBL] [Abstract][Full Text] [Related]
10. Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia.
Hattori A; Tsunoda M; Konuma T; Kobayashi M; Nagy T; Glushka J; Tayyari F; McSkimming D; Kannan N; Tojo A; Edison AS; Ito T
Nature; 2017 May; 545(7655):500-504. PubMed ID: 28514443
[TBL] [Abstract][Full Text] [Related]
11. Identification of a Musashi2 translocation as a novel oncogene in myeloid leukemia.
Spinler K; Hamilton M; Bajaj J; Shima Y; Diaz E; Kritzik M; Reya T
bioRxiv; 2023 Dec; ():. PubMed ID: 38234720
[TBL] [Abstract][Full Text] [Related]
12. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL.
Horita M; Andreu EJ; Benito A; Arbona C; Sanz C; Benet I; Prosper F; Fernandez-Luna JL
J Exp Med; 2000 Mar; 191(6):977-84. PubMed ID: 10727459
[TBL] [Abstract][Full Text] [Related]
13.
Negi V; Vishwakarma BA; Chu S; Oakley K; Han Y; Bhatia R; Du Y
Oncotarget; 2017 Nov; 8(58):98853-98864. PubMed ID: 29228732
[TBL] [Abstract][Full Text] [Related]
14. [Preliminary study of proteins related to blast crisis in chronic myeloid leukemia].
Zhu HQ; Liu XL; Li R; Du QF; Zhang S; Yao F; Liu Z
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):655-9. PubMed ID: 20021859
[TBL] [Abstract][Full Text] [Related]
15. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
Liu XL; Zhou SY; Du QF; Zheng WY; Zhang S; Song LL; Xu B; Liu QF; Meng FY
Ai Zheng; 2004 Apr; 23(4):421-5. PubMed ID: 15087031
[TBL] [Abstract][Full Text] [Related]
16. Musashi2 modulates K562 leukemic cell proliferation and apoptosis involving the MAPK pathway.
Zhang H; Tan S; Wang J; Chen S; Quan J; Xian J; Zhang Ss; He J; Zhang L
Exp Cell Res; 2014 Jan; 320(1):119-27. PubMed ID: 24076374
[TBL] [Abstract][Full Text] [Related]
17. A novel gene, MSI2, encoding a putative RNA-binding protein is recurrently rearranged at disease progression of chronic myeloid leukemia and forms a fusion gene with HOXA9 as a result of the cryptic t(7;17)(p15;q23).
Barbouti A; Höglund M; Johansson B; Lassen C; Nilsson PG; Hagemeijer A; Mitelman F; Fioretos T
Cancer Res; 2003 Mar; 63(6):1202-6. PubMed ID: 12649177
[TBL] [Abstract][Full Text] [Related]
18. Histone demethylase RBP2 mediates the blast crisis of chronic myeloid leukemia through an RBP2/PTEN/BCR-ABL cascade.
Yin X; Zhou M; Fu Y; Yang L; Xu M; Sun T; Wang X; Huang T; Chen C
Cell Signal; 2019 Nov; 63():109360. PubMed ID: 31374292
[TBL] [Abstract][Full Text] [Related]
19. Detection of P210bcr-abl in mature granulocytes from Ph1-positive chronic myelogenous leukemia patients by an immunoblotting method.
Kuwao F; Takahashi I
Leukemia; 1993 Aug; 7(8):1168-73. PubMed ID: 8350617
[TBL] [Abstract][Full Text] [Related]
20. No correlation between locations of bcr breakpoints and clinical states in Ph1-positive CML patients.
Ogawa H; Sugiyama H; Soma T; Masaoka T; Kishimoto S
Leukemia; 1989 Jul; 3(7):492-6. PubMed ID: 2733454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
